A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll-like receptor agonists-Reference-Cited by-同舟云学术

A macrophage marker, siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll-like receptor agonists

Published:2007 Issue:3 Volume:56 Page:1010-1020
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

York Michael R.,Nagai Taro,Mangini Alyson J.,Lemaire Raphaël,van Seventer Jean Maguire,Lafyatis Robert

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference52 articles.

1. In: , editors. Systemic sclerosis. 2nd ed. Philadelphia: Lipincott Williams & Wilkins; 2004.

2. Interleukin-1, Interleukin-2, Interleukin-4, Interleukin-6, Tumor Necrosis Factor α, and Interferon-γ Levels in Sera from Patients With Scleroderma

3. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis

4. . Pathogenesis: emphasis on human data. In: , editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 63–97.

Cited by 273 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toll-like Receptor Homologue CD180 Ligation of B Cells Upregulates Type I IFN Signature in Diffuse Cutaneous Systemic Sclerosis;International Journal of Molecular Sciences;2024-07-20

2. Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans;Journal of Experimental Medicine;2024-05-23

3. Sialic Acid–Siglec-E Interactions Regulate the Response of Neonatal Macrophages to Group B Streptococcus;ImmunoHorizons;2024-05-01

4. Early antiretroviral therapy in SIV-infected rhesus macaques reveals a multiphasic, saturable dynamic accumulation of the rebound competent viral reservoir;PLOS Pathogens;2024-04-09

5. HRI Inhibition by Hemin as a Novel Targeted Therapy for Glioblastoma via the Integrated Stress Response;2024-04-09